2.4850
+0.0150
+(0.61%)
As of 3:54:46 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -0.24 | -0.27 | -0.95 | -1.13 |
| Low Estimate | -0.27 | -0.38 | -1.08 | -1.43 |
| High Estimate | -0.21 | -0.21 | -0.87 | -0.84 |
| Year Ago EPS | -0.34 | -0.44 | -1.33 | -0.95 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 10 | 10 |
| Avg. Estimate | -- | -- | -- | 5.09M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 50.9M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.33 | -0.34 | -0.26 |
| EPS Actual | -0.34 | -0.44 | -0.22 | -0.22 |
| Difference | -0.02 | -0.11 | 0.12 | 0.04 |
| Surprise % | -7.59% | -35.09% | 36.23% | 15.38% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.27 | -0.95 | -1.13 |
| 7 Days Ago | -0.25 | -0.28 | -0.96 | -1.17 |
| 30 Days Ago | -0.25 | -0.28 | -0.96 | -1.17 |
| 60 Days Ago | -0.27 | -0.28 | -1.06 | -1.09 |
| 90 Days Ago | -0.27 | -0.28 | -1.06 | -1.09 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 3 | -- | 1 |
| Up Last 30 Days | 1 | 1 | -- | 1 |
| Down Last 7 Days | -- | 1 | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RZLT | 28.99% | 38.96% | 28.36% | -19.12% |
| S&P 500 | 6.40% | 6.07% | 9.36% | 14.28% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/13/2025 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 2/13/2025 |
| Reiterates | Guggenheim: Buy to Buy | 2/10/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/5/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/8/2024 |
| Initiated | Wedbush: Outperform | 11/5/2024 |
Related Tickers
FHTX Foghorn Therapeutics Inc.
3.4800
+7.74%
RLAY Relay Therapeutics, Inc.
2.4100
+8.56%
NUVB Nuvation Bio Inc.
2.0150
+15.14%
FATE Fate Therapeutics, Inc.
1.0600
+13.34%
GPCR Structure Therapeutics Inc.
15.89
+5.58%
LXEO Lexeo Therapeutics, Inc.
1.9850
-8.53%
TECX Tectonic Therapeutic, Inc.
16.11
-3.45%
PHAR Pharming Group N.V.
8.05
+0.25%
TARS Tarsus Pharmaceuticals, Inc.
46.45
+5.28%
FENC Fennec Pharmaceuticals Inc.
5.0000
-0.20%